▶주메뉴 바로가기
▶본문 바로가기
Celltrion Pharm, the generic arm of Celltrion, announced Nov. 14 that its sales jumped 36.6 percent in the third quarter from a year earlier to 47.43 billion won ($40.7 million). The South Korean co...
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization. The company emphasized that it is the firs...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million). Its sales increased by 46.4 pe...
GOTTINGEN, Germany -- Behind the market expansion of Samsung’s biologics business is 149-year-old Sartorius, a German firm that has helped it grow rapidly. Founded in 1870, the German company suppli...
South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen. Under the partnership, Biogen will be...
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icu...
Bio company SillaJen announced Oct. 31 it will pay back 110 billion won (94.25 million), which it received by issuing convertible bonds, to Kiwoon Securities in March. “The annual interest rate for ...
South Korea’s Health Ministry said Oct. 30 that it is considering revoking Kolon Life Science’s innovative drug company certification for mislabeling and falsely reporting ingredients in its gene the...
Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales o...
The 30th CPhI Worldwide 2019, the biggest global event of the year for the pharmaceutical industry, is set to take place at Messe Frankfurt in Germany from Nov. 5 to 7. Every year, CPhI brings toget...
South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing. The company applied for approval Sept. 3 and expects to be ...
The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports. The problematic products were produ...
Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada. It is the first South Korean company to enter the Canadian market with a botulinum tox...
South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11. The court’s recent ...
Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota. “Medytox is saying that...
Proptech startup Kasa Korea attracts W9.2b in series B funding
Korean lenders struggle with New York hotel-retail project investment
Netmarble launches storytelling game BTS Universe Story, second collaboration with BTS
Coupang delves into computer parts biz, outcompeting go-betweens
How once rising sports platform TLX Pass fell
W520b per BTS member? Market worth of K-pop stars in limelight as agency’s IPO nears
Litigations pile pressure on Mirae Asset Group
LG Chem to decide acquisition of Nissan factory in Spain within this month
September 28, 2020
